我要投票 佛仁制药在医疗器械行业中的票数:558
· 外 推 电 报 ·
2026-01-09 16:13:59 星期五

【佛仁制药是哪个国家的品牌?】

佛仁制药是什么牌子?「佛仁制药」是 甘肃佛仁制药科技有限公司 旗下著名品牌。该品牌发源于陇南市,由创始人曹明月在2004-03-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力佛仁制药品牌出海!将品牌入驻外推网,定制佛仁制药品牌推广信息,可以显著提高佛仁制药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

甘肃佛仁制药科技有限公司是在收购原甘肃武都制药厂的基础上重新组建的一家股份制企业,主要利用地方特色药材资源,从事中成药产品的生产经营,有40多年的生产历史。2010年1月再次通过了国家GMP认证,是药品生产国家GMP认证企业。具有“国药准字”批准文号的产品46个,其中14个品种是2009年国家新选定的国家基本药物。

公司座落于陇南市武都工业园区,占地面积为43亩,建筑面积为5800平方米,总投资为2745万元,形成固定资产投资1120万元。建有中药材前处理、中药提取、综合制剂和动力维修四个车间,拥有片剂、丸剂、颗粒剂、散剂四条生产线。再建的生产线有胶囊剂、糖浆剂、酊剂、煎膏剂、流浸膏剂,以及中药饮片车间。

安装有35000m3/h风量的空气净化装置,总体净化级别达到了10万级,高出了国家要求。设有新产品开发研究所和产品检验质保中心。公司整体生产设备齐全,检验仪器齐全。年具有生产丸剂1000吨(大蜜丸500吨、水丸320吨、浓缩丸180吨),片剂4亿片、颗粒剂2000万袋、散剂300万袋的生产能力。

企业组织机构健全,人员结构合理。现有职工96人,各类专业技术人员占员工总数的28%。企业通过不断的技术改造,采取新工艺,购置新设备,在努力提高产品质量的同时,以务实诚信为经营理念,企业品牌的建设和产品影响力已初具规模,公司为了更及时快捷的给客户提供服务,特在郑州设立全国营销中心,面向全国进行推广,产品遍及全国各地30多个省市。2013年实现销售收入3000多万元,上缴税金200多万元,预计2014年销售收入可达近5000万元,利税在420万元以上。

甘肃佛仁制药科技有限公司无论是产品的技术优势还是市场优势,都具有广阔的发展前景。我们会把可持续发展战略相关产业链上的工作和包括环境保护在内的各项工作做的更好,为推动地方中药材持续发展,带动药农脱贫致富,解决下岗职工再就业,为人类社会和经济的发展做出应有的贡献。


英文翻译:Gansu Furen pharmaceutical science and Technology Co., Ltd. is a joint-stock enterprise re established on the basis of the acquisition of the former Gansu Wudu pharmaceutical factory. It mainly uses local characteristic medicinal materials resources to engage in the production and operation of Chinese patent medicine products, with a production history of more than 40 years. In January 2010, it passed the national GMP certification again, and is a national GMP certification enterprise for drug production. There are 46 products with the approval number of "Guoyao Zhunzi", 14 of which are national essential drugs newly selected by the state in 2009. The company is located in Wudu Industrial Park, Longnan City, covering an area of 43 mu, a building area of 5800 square meters, with a total investment of 27.45 million yuan, forming a fixed asset investment of 11.2 million yuan. There are four workshops for Chinese medicine pretreatment, Chinese medicine extraction, comprehensive preparation and power maintenance, and four production lines for tablets, pills, granules and powders. The newly built production lines include capsule, syrup, tincture, decocting agent, liquid extract, and herbal pieces workshop. The air purification device with 35000m3 / h air volume is installed, and the overall purification level has reached 100000, which is higher than the national requirements. There are new product development research institute and product inspection and Quality Assurance Center. The company has complete production equipment and inspection instruments. The annual production capacity is 1000 tons of pills (500 tons of honey pills, 320 tons of water pills and 180 tons of concentrated pills), 400 million tablets, 20 million bags of granules and 3 million bags of powder. The organizational structure of the enterprise is sound and the personnel structure is reasonable. At present, there are 96 employees, 28% of which are professional technicians. Through continuous technological transformation, adopting new technology and purchasing new equipment, while striving to improve the quality of products, the company has established a national marketing center in Zhengzhou to provide services to customers in a more timely and efficient manner, with pragmatic and honest business philosophy, and its brand building and product influence has taken shape. Its products are spread all over the country Multiple provinces and cities. In 2013, the company realized sales revenue of more than 30 million yuan and paid taxes of more than 2 million yuan. It is estimated that in 2014, the sales revenue will reach nearly 50 million yuan and the profit and tax will be more than 4.2 million yuan. Gansu Furen pharmaceutical science and Technology Co., Ltd. has broad prospects for development, both in terms of technical advantages and market advantages. We will do a better job in the industry chain related to the sustainable development strategy and in various works including environmental protection, in order to promote the sustainable development of local traditional Chinese medicine, drive pharmaceutical farmers out of poverty and become rich, solve the problem of reemployment of laid-off workers, and make due contributions to the development of human society and economy.

本文链接: https://www.waitui.com/brand/559930f52.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

福建铁路公司注册资本增至377.1亿,增幅约15%

36氪获悉,爱企查App显示,近日,福建铁路有限公司发生工商变更,注册资本由约328.1亿人民币增至约377.1亿人民币,增幅约15%。

14分钟前

日联科技:已完成收购SSTI 66%股权

36氪获悉,日联科技公告,公司全资子公司新加坡瑞泰已按照协议约定支付本次交易的股权收购款,并取得 SSTI 66%股权,本次股权交割已完成。

14分钟前

正海生物:公司取得医疗器械注册证

36氪获悉,正海生物公告,公司于近日取得国家药品监督管理局下发的《中华人民共和国医疗器械注册证》,产品名称为钙硅生物陶瓷口腔骨修复材料,注册证编号为国械注准20263170015,有效期至2031年1月6日。该产品适用于牙槽骨缺损修复,采用三维打印方式成型,具备定制化生产潜力。此注册证的取得将丰富公司口腔领域产品线,提升市场竞争力。但产品上市后实际销售情况取决于市场推广效果,对公司未来业绩的影响无法准确预测。

14分钟前

闲鱼:2025年二次元、追星与游戏用户总量已突破1.6亿

36氪获悉,《2025闲鱼次元年度报告》显示,截至2025年底,闲鱼二次元、追星与游戏用户总量已突破1.6亿,年度二次元消费人数同比增长47%,平台已成为年轻人兴趣消费的首选阵地。

14分钟前

绿地控股:预计2025年净亏损160亿元-190亿元

36氪获悉,绿地控股公告,预计2025年归属于母公司所有者的净利润为-190亿元到-160亿元。上年同期为-155.52亿元。受资产价格持续下行、公司加大促销去化力度、部分项目开发周期延长等多种因素的影响,基于谨慎性原则,公司对存在风险的存货拟计提减值准备;由于市场有效需求不足、社会预期偏弱,公司房地产业的结转规模、基建产业的营收规模同比均有较大幅度的下降,公司房地产业结转毛利率也同比下降,导致业绩进一步承压;房地产项目利息资本化减少,计入当期财务费用的利息支出增加。

14分钟前

本页详细列出关于佛仁制药的品牌信息,含品牌所属公司介绍,佛仁制药所处行业的品牌地位及优势。
咨询